ISRCTN76960238
Completed
Not Applicable
A randomised, double-blind, placebo-controlled phase IV trial to assess the clinical benefit of Genacol®, a food supplement made of a proprietary collagen hydrolysate (1200 mg/day), over a period of 24 weeks, in subjects with joint pain at the lower, upper limbs or at the lumbar spine
utraveris (France)0 sites200 target enrollmentFebruary 22, 2010
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Joint pain
- Sponsor
- utraveris (France)
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women over 50 years with joint pain (hip, knee, elbow, shoulder, hand and lumbar spine) over 30 mm on a 0\-100 mm visual analogue scale.
Exclusion Criteria
- •1\. Unlikely to cooperate in the study
- •2\. Poor compliance anticipated by the investigator
- •3\. Participating in another trial at the same time or within the previous 1 month with active therapeutic intervention (except if the patient only performed the screening visit without taking the tested supplement)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to investigate if use of FOL-005 can increase hair growth.EUCTR2017-003809-17-DEFollicum AB60
Completed
Not Applicable
A double-blind, randomised, placebo-controlled phase III study of the efficacy of a bivalent Pseudomonas aeruginosa flagella vaccine in patients with cystic fibrosisCystic fibrosisNutritional, Metabolic, EndocrineISRCTN98785888The Society for the fight of Cystic Fibrosis (The Gesellschaft zur Bekämpfung der Mukoviszidose e.V.) (Germany)483
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablets.EUCTR2006-005263-26-ESALK-Abelló, S.A.
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral infection for the prevention or attenuation of asthma symptoms caused by respiratory virusesEUCTR2009-017480-42-GBSynairgen Research Ltd147
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral infection for the prevention or attenuation of COPD symptoms caused by respiratory viruses - Phase II: Inhaled SNG001 in COPD subjectsEUCTR2010-022110-29-GBSynairgen Research Limited166